Full-Time

Senior/Staff Firmware Engineer

Confirmed live in the last 24 hours

SERES

SERES

201-500 employees

Develops microbiome-based therapies for diseases

No salary listed

Senior, Expert

Milpitas, CA, USA

Category
Embedded Engineering
Software Engineering
Required Skills
Bash
Python
AUTOSAR
MATLAB
Simulink
C/C++
Requirements
  • M.S. or higher degree in Computer Science, Electrical Engineering, Computer Engineering, or related field
  • 5+ years of experience in firmware development, preferably with vertically integrated automotive system level product
  • Expert in C programming, ideally familiar with C++, Python, and bash scripting
  • Proficiency with real time operating system platforms, ideally in safety critical applications
  • Expert knowledge of embedded microprocessor tools, hardware peripherals such as ADC, GPIO, PWM and SPI, and common buses CAN interface and corresponding driver code generation
  • Hands-on experience debugging in real world environments with embedded diagnostics tooling such as oscilloscopes, logic analyzers, JTAG etc. and general Vector data analysis tools
  • Ability to travel abroad 15% yearly
Responsibilities
  • Development of real-time embedded software that implements control and safety management of the Drive Inverter
  • Develop automated tests to ensure high quality software releases and accurate functionality
  • Be involved in the full life cycle of firmware development from concept through integration, test, and release to our growing fleet of vehicles
  • Work closely with the hardware and control teams to specify hardware actuation and sensing requirements
  • Develop and optimize firmware for motor controls and power electronics
  • Implement the firmware on hardware with C code or through model-based design tool such as MATLAB/Simulink, ensuring AUTOSAR compliance and seamless hardware integration
  • Design and specify the software architecture
  • Specify, design, and implement tool for embedded subsystems
  • Driver development, hardware testing debugging, and component/vehicle bring-up
  • Design testing and calibration tool in the test bench
  • Identify the root cause of component or vehicle issues and lead cross function team to deliver the solution
  • Optimize the embedded code for the product requirements
  • Collaborate with control team to deliver the firmware release
Desired Qualifications
  • Experience with MCU development with Renesas, ST, Infineon, NXP, or TI is preferred
  • Experience with UDS and OTA development for vehicle applications is preferred
  • Experience with AUTOSAR firmware development for vehicle applications is preferred
  • Experience with model-based development for vehicle applications is preferred
  • Experience with ASPICE development process and ISO 21434 & ISO 26262 on vehicle applications is preferred
  • Knowledge of version control (Git) and continuous integration (Jenkins) preferred
  • Previous work in startup or high-growth tech settings is a plus
  • Highly collaborative mindset and good communication skills
  • Proactive, self-directed, and good at estimating project scope and timelines

Seres Therapeutics develops microbiome-based therapies that use beneficial bacteria to treat diseases, particularly focusing on conditions like Clostridium difficile infection (CDI) and other gastrointestinal disorders. Their approach aims to restore the natural balance of bacteria in the human body, addressing the root causes of these diseases. Unlike many traditional treatments that may only alleviate symptoms, Seres targets the underlying issues through its innovative therapies. The company collaborates with healthcare providers and research institutions to enhance its solutions and operates in the biopharmaceutical market, which is known for its growth potential. Seres generates revenue from the sale of its approved therapies and licensing agreements, while heavily investing in research and development to bring new treatments to market. The goal of Seres Therapeutics is to transform patient lives by providing effective microbiome-based treatments that meet unmet medical needs.

Company Size

201-500

Company Stage

IPO

Headquarters

Cambridge, Massachusetts

Founded

2010

Simplify Jobs

Simplify's Take

What believers are saying

  • Increased interest in microbiome therapies could lead to more partnerships and funding.
  • FDA approval trends may expedite regulatory processes for Seres' future products.
  • Growing demand for personalized medicine aligns with Seres' microbiome-based treatments.

What critics are saying

  • Leadership changes may disrupt strategic continuity and corporate governance.
  • Reliance on milestone payments from Nestlé could create financial instability.
  • Sale of VOWST business may limit future revenue streams and market presence.

What makes SERES unique

  • Seres Therapeutics pioneers microbiome-based therapies, targeting root causes of diseases.
  • The company has a strong focus on R&D and clinical trials for innovative treatments.
  • Seres collaborates with healthcare providers and research institutions to advance therapeutic solutions.

Help us improve and share your feedback! Did you find this helpful?

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

-2%

2 year growth

14%
TipRanks
Feb 27th, 2025
Seres Therapeutics Announces CMO Resignation in March 2025

Lisa von Moltke will resign from Seres Therapeutics in March 2025.

Benzinga
Jan 16th, 2025
Seres Therapeutics Announces Receipt Of Expected $50 Million Installment Payment Related To Vowst Sale

CAMBRIDGE, Mass., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. MCRB (Seres or the Company), a leading live biotherapeutics company, announced today the receipt of a $50 million installment payment related to the Company's previously announced sale of its VOWST business to Société des Produits Nestlé S.A (SPN, and with certain of its affiliates, collectively, Nestlé Health Science). This installment payment was expected as Seres is fulfilling its transition obligations. As previously announced, based on the Company's existing cash, inclusive of this payment, a projected installment payment from Nestlé Health Science in July 2025 of $25 million (less up to approximately $1.5M in employment-related payments to Nestlé Health Science), transaction-related obligations and current operating plans, the Company expects to fund operations into the first quarter of 2026. About Seres Therapeutics  Seres Therapeutics, Inc. MCRB is a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics

Stock Titan
Dec 16th, 2024
Xilio Therapeutics Appoints Caroline Hensley as Chief Legal Officer

Hensley joins from Seres Therapeutics, where she served as senior vice president, assistant general counsel and chief compliance officer, overseeing corporate legal and compliance matters.

Investing.com
Aug 6th, 2024
Seres Therapeutics secures $175M in Nestlé deal

Seres Therapeutics secures $175M in Nestlé deal.

Pharmalive
Jun 12th, 2024
Flagship Pioneering and ProFound Therapeutics announce agreement to identify novel first-in-class therapeutics for the treatment of obesity under strategic partnership with Pfizer

CAMBRIDGE, Mass., June 12, 2024 - Flagship Pioneering and ProFound(TM) Therapeutics, a Flagship-founded company pioneering the expanded human proteome to develop novel medicines for a multitude of diseases, today announced a collaboration to conduct foundational research to identify potential next-generation first-in-class therapies for the treatment of obesity.